Area of research
Epidemiology · Hepatology
Research interest
Research interests include Liver Disease Diagnosis and Treatment, Liver Disease and Transplantation, Diet, Metabolism, and Disease, and Hepatitis C virus research.
Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial
Limitations of Guideline‐Recommended Risk Stratification in Identifying <scp>MASLD</scp> Patients for Novel Drug Treatments
Systematic Sex-Based Inequity in the MELD Score-Based Allocation System for Liver Transplantation in Germany
Soluble urokinase plasminogen activator receptor is a prognostic biomarker in decompensated cirrhosis
Impact of Handling Perception and Language Barriers on Virologic Response to Daily Subcutaneous Bulevirtide in Hepatitis D
Fungal signature differentiates alcohol-associated liver disease from nonalcoholic fatty liver disease
Amendment „Neue Nomenklatur zur MASLD (Metabolic Dysfunction Associated Steatotic Liver Disease; metabolische Dysfunktion assoziierte steatotische Lebererkrankung)“ zur S2k-Leitlinie „Nicht-alkoholische Fettlebererkrankung“ (v.2.0/April 2022) der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS)
Treating hepatitis D with bulevirtide – Real-world experience from 114 patients
Any alcohol use in NAFLD patients is associated with significant changes to the intestinal virome
Liver fat as risk factor of hepatic and cardiometabolic diseases
Validation of risk scores for allograft failure after liver transplantation in Germany: a retrospective cohort analysis
Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: A <scp>FIDELITY</scp> subgroup analysis
Clinical characteristics of patients with non-alcoholic fatty liver disease (NAFLD) in Germany – First data from the German NAFLD-Registry
Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – April 2022 – AWMF-Registernummer: 021–025
Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis
Cenicriviroc for the treatment of COVID-19: first interim results of a randomised, placebo-controlled, investigator-initiated, double-blind phase II trial
Bulevirtide treatment of hepatitis D in Germany: multicentre real-world experience
Complement activation induces excessive T cell cytotoxicity in severe COVID-19
The fecal mycobiome in non-alcoholic fatty liver disease
NAFLD and cardiovascular diseases: a clinical review
Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease
The role of the innate immune system in the development and treatment of hepatocellular carcinoma
Phenotyping non‐alcoholic fatty liver disease by the gut microbiota: Ready for prime time?
High Protein Intake Is Associated With Histological Disease Activity in Patients With NAFLD
Maternal exercise conveys protection against NAFLD in the offspring via hepatic metabolic programming
Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial
Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis
Could inherited predisposition drive non-obese fatty liver disease? Results from German tertiary referral centers
Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study
S2k-Leitlinie nicht alkoholische Fettlebererkrankungen